



Istituto Superiore di Sanità
Rome, Italy
October 1-3, 2008

INTERNATIONAL MEETING

NEEDS AND CHALLENGES IN TRANSLATIONAL MEDICINE: *Filling the Gap between Basic Research and Clinical Applications*

SCIENTIFIC PROGRAMME

DAY 1 (WEDNESDAY, OCTOBER 1, 2008)

REGISTRATION (8:30 – 9:30)

Opening Ceremony

9:30 – 10:00

E. Garaci, President, Italian National Institute of Health
F. Fazio, Subsecretary, Italian Ministry of Labour and Social Welfare
G. Zotta, Director, Department of Innovation, Italian Ministry of Labour and Social Welfare
L. Maiani, President, Italian National Research Council
R. Levi-Montalcini (Nobel Laureate, 1986)

Session 1 CANCER (10:00 – 15:00)

10:00 – 10:20	P. Boyle (France)	The global problem of cancer: the priority to develop translational research
10:20 – 10:40	C. Croce (USA)	Micro-RNAs and perspectives for cancer therapy
10:40 – 11:00	L. Liotta (USA)	Cancer proteomics in the discovery of new biomarkers for diagnosis and treatment
11:00 – 11:20	M. Pierotti (Italy)	Challenges for translation research on cancer and the role of 'Alliance against Cancer' in Italy
11:20 – 11:40	Coffee Break	
11:40 – 12:00	G. J. Nabel (USA)	Genetic, cellular and immune approaches to cancer and infectious diseases
12:00 – 12:20	F. Marincola (USA)	Gene profiling for the prediction of tumor response to treatment: the case of immunotherapy
12:20 – 12:40	C. J. Melief (The Netherlands)	Tumor-specific immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 peptides vaccine: perspectives for the development of therapeutic vaccines

12:40 – 13:00	F. Fazio (Italy)	Novel imaging strategies for the detection and monitoring of cancer
13:00 – 13:10	Selected Oral Presentation	
13:10 – 13:20	Selected Oral Presentation	
Lunch		
13:20 – 15:00	POSTER SESSION	

Session 2 NEUROSCIENCES (15:00 – 17:40)

15:00 – 15:20	C. Masters (Australia)	Rational therapeutic strategies for modifying Alzheimer's disease: translating basic research on Abeta amyloid oligomers
15:20 – 15:40	K. Nave (Germany)	Inherited demyelinating neuropathies: from basic to clinical research
15:40 – 16:00	M. Salvetti (Italy)	Multiple sclerosis: pharmacogenomics and personalized drug treatment
16:00 – 16:20	Coffee Break	
16:20 – 16:40	K. P. Lesch (Germany)	Genetics and epigenetic factors in anxiety and depression: from animal model to psychiatric interventions
16:40 – 17:00	F. Cornelio (Italy)	Challenges for translation research in biomedicine and the role of the Italian Network on Neurosciences
17:00– 17:20	R. Will (UK)	Creutzfeldt-Jakob Disease and translational medicine
17:20– 17:30	Selected Oral Presentation	
17:30– 17:40	Selected Oral Presentation	

DAY 2 (THURSDAY, OCTOBER 2, 2008)

Session 3 RARE DISEASES (9:00 – 11:20)

9:00-9:20	S.C. Groft (USA)	The role of the NIH Office of Rare Diseases in fostering translational research
9:20-9:40	L. Villard (France)	The European Network on Rett syndrome
9:40-10:00	G. Merlini (Italy)	Amyloidosis: molecular mechanisms and targeted therapy
10:00-10:20	A. Ballabio (Italy)	Block of autophagy in lysosomal storage disorders and therapeutic implications
10:20-10:40	S. Garattini (Italy)	Clinical trials for the treatment of rare diseases

10:40-10:50	Selected Oral Presentation
10:50-11:00	Selected Oral Presentation
11:00-11:20	Coffee Break

Session 4 CARDIOVASCULAR DISEASES (11:20 – 15:00)

11:20-11:40	G. Condorelli (Italy)	Stem cells for cardiomyocyte regeneration: state of the art
11:40-12:00	M. H. Yacoub (UK)	Heart failure: from basic research to clinical applications
12:00-12:20	A. Mantovani (Italy)	The long pentraxin PTX3 in vascular pathology
12:20-12:40	M. Bartoli (USA)	Molecular mechanisms of retinal vessel dysfunction and clinical implications
12:40-13:00	A. Dominiczak (UK)	Proteomic biomarkers in coronary artery disease
13:00-13:20	A. M. Zeiher (Germany)	Cell based therapy of myocardial infarction
13:20-13:30	Selected Oral Presentation	
13:30-13:40	Selected Oral Presentation	
13:40-15:00	Lunch	
	POSTER SESSION	

Session 5 INFECTIOUS AND AUTOIMMUNE DISEASES (15:00 – 17:40)

15:00-15:20	H. Hengartner (Switzerland)	Immune response to viral infection: challenges for therapeutic intervention
15:20-15:40	B. Autran (France)	Perspectives for immunotherapy of HIV infection
15:40-16:00	B. Singh (Canada)	Regulation of autoimmune diseases
16:00-16:20	Coffee Break	
16:20-16:40	A. D. Santin (USA)	Therapeutic dendritic cell-based vaccines against HPV-induced tumors

16:40-17:00	P. von Landenberg (Germany)	TLRs and autoimmune diseases
17:00-17:20	V. Barnaba (Italy)	Insights into the relationships between viral infection and autoimmune diseases: implications for immunotherapy interventions
17:20-17:30	Selected Oral Presentation	
17:30-17:40	Selected Oral Presentation	

DAY 3 (FRIDAY, OCTOBER 3, 2008)

Session 6 CRITICAL REGULATORY ISSUES FOR PROMOTING BIOMEDICAL TRANSLATIONAL RESEARCH (9:00 – 11:20)

9:00-9:20	H.-G. Eichler (UK)	EMA's role and activities for promoting translational medicine in Europe
9:20-9:40	C. L. Julou (Belgium)	The sponsors' point of view on the critical regulatory issues at European level impacting on translation from laboratory to bedside
9:40-10:00	G. Migliaccio (Italy)	Towards a European harmonisation of the requirements for first clinical use of advanced therapy medicinal products: preclinical requirements for cell-based medicinal products
10:00-10:20	M. C. Galli (Italy)	Towards a European harmonisation of the requirements for first clinical use of advanced therapy medicinal products: preclinical requirements for gene therapy medicinal products
10:20-10:40	U. Kalinke (Germany)	How implementation of the European clinical trials directive has impacted on the approach to translational medicine in Germany
10:40-11:00	H.M. Buchanan-Smith (UK)	The state of the art of regulatory aspects of the use of animals in biomedical studies: the case of non-human primates
11:00-11:20	Coffee break	

Session 7 NATIONAL AND INTERNATIONAL INITIATIVES FOR PROMOTING BIOMEDICAL TRANSLATIONAL AND CLINICAL RESEARCH (11:20 – 13:10)

11:20-11:35	L. Matrisian (USA)	The role of the NCI in promoting translational research on cancer
11:35-11:50	R. Balling (Germany)	EATRIS: towards a European infrastructure for the biomedical translational research
11:50-12:05	J. Demotes-Mainard (France)	ECRIN: towards a European infrastructure for clinical trials and biotherapies
12:05-12:20	K. Zatloukal (Austria)	The European initiative for Biobanks
12:20-12:35	G. Tocchini-Valentini (Italy)	INFRAFRONTIER: the European infrastructure for phenotyping and archiving of model mammalian genomes
12:35-12:50	F. Belardelli (Italy)	The Italian initiative for biomedical translational research
12:50-13:05	K. Strandgaard (Belgium)	The Innovative Medicine Initiative (IMI) and challenges in translational research
13:05-13:20	U. Ringborg (Sweden)	Coordinating translational cancer research in Europe: a need

13:20-13:30

E. Garaci (Italy)

CLOSING REMARKS

SCIENTIFIC COMMITTEE

E. Garaci (Honorary President)
R. Balling (Germany)
F. Belardelli (Italy)
J. Demotes-Mainard (France)
F. Fazio (Italy)
S. Garattini (Italy)
F. Marincola (USA)
M. Pierotti (Italy)
K. Zatloukal (Austria)

LOCAL ORGANIZING COMMITTEE

E. Alleva
M. Ferrantini
C. Lombardo
G. Migliaccio
M. Minetti
T. Petrucci
M. Pocchiari
F. Podo
M. Tartaglia
D. Taruscio

ORGANIZING SECRETARIAT

C. D'Addazio
A. Ferrigno
F. Moretti
M. Romero
E. Rosa
U. Visconti

INVITED SPEAKERS AND CHAIRPERSONS

Enrico Alleva, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Brigitte Autran, Laboratoire d'Immunologie Cellulaire, INSERM U543, Hôpital Pitié-Salpêtrière, Paris, France

Andrea Ballabio, Telethon Institute of Genetics and Medicine (TIGEM), Napoli, Italy

Rudi Balling, Scientific Director, Helmholtz Centre for Infection Research, Braunschweig, Germany

Vincenzo Barnaba, Department of Internal Medicine, University of Rome "La Sapienza", Rome, Italy

Manuela Bartoli, Department of Ophthalmology, University of South Carolina School of Medicine, Columbia, USA

Filippo Belardelli, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Peter Boyle, International Agency for Research on Cancer

Hannah Buchanan-Smith, Department of Psychology, University of Stirling, Scotland, UK

Antonio Cassone, Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy

Gianluigi Condorelli, National Research Council, Rome, Italy

Ferdinando Cornelio, Scientific Director, Neurological Institute Foundation "C. Besta", Milan, Italy

Carlo M. Croce, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA

Ruggiero De Maria, Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

Jacques Demotes-Mainard, CIC INSERM / CHU de Bordeaux, CHU Haut-Lévêque, Pessac, France

Anna Dominiczak, Cardiovascular Research Centre, University of Glasgow, Scotland, UK

Hans-Georg Eichler, European Medicines Agency (EMA), UK

Barbara Ensoli, National AIDS Center, Istituto Superiore di Sanità, Rome, Italy

Ferruccio Fazio, Subsecretary, Italian Ministry of Labour and Social Welfare

Luigi Frati, University of Rome "La Sapienza", Rome, Italy

Maria Cristina Galli, Istituto Superiore di Sanità, Rome, Italy

Enrico Garaci, President, Istituto Superiore di Sanità, Rome, Italy

Silvio Garattini, Director, Mario Negri Institute for Pharmacological Research, Milan, Italy

Stephen C. Groft, Office of Rare Diseases, National Institutes of Health, Bethesda, MD, USA

Hans Hengartner, Institute of Experimental Immunology, University Hospital Zurich, Zürich, Switzerland

Christine-Lise Jolou, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium

Ulrich Kalinke, Paul-Ehrlich-Institut, 63225 Langen, Germany

Philipp von Landenberg, Institut für Klinische Chemie und Laboratoriumsmedizin, Johannes Gutenberg Universität Mainz, Mainz, Germany

Klaus P. Lesch, Department of Psychiatry and Psychotherapy, Molecular and Clinical Psychobiology, University of Würzburg, Germany

Rita Levi-Montalcini, President, European Brain Research Institute, Rome, Italy

Lance A. Liotta, Director, George Mason University, Center for Proteomics & Molecular Medicine, Fairfax, USA

Luciano Maiani, National Research Council, Italy

Alberto Mantovani, Istituto Clinico Humanitas, Milan, Italy

Francesco M. Marincola, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, USA

Nello Martini, Italian Medicine Agency, Roma, Italy

Colin L. Masters, Department of Pathology, The University of Melbourne, Victoria, Australia

Lynn Matrisian, National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD, USA

Cornelis J. M. Melief, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands

Giampaolo Merlini, Center for Research and Treatment of Systemic Amyloidoses, Fondazione IRCCS, Policlinico San Mateo, Pavia, Italy

Giovanni Migliaccio, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Gary J. Nabel, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

Klaus A. Nave, Department of Neurogenetics, Max Planck Institute of Experimental Medicine, Göttingen, Germany

Giorgio Parmiani, San Raffaele Scientific Institute, Milano, Italy

Pier G. Pelicci, Department of Experimental Oncology, European Institute of Oncology, Campus IFOM-IEO, Milan, Italy

Marco Pierotti, Scientific Director, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Carlo Pini, Center for Immunobiologicals Research and Evaluation (CRIVIB), Istituto Superiore di Sanità, Rome, Italy

Maurizio Pocchiari, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy

Ulrik Ringborg, Professor, Director of Cancer Center Karolinska Institutet, Stockholm, Sweden

Marco Salvetti, Department of Neurology, Center for Experimental Neurological Therapy, Santa Andrea Hospital, University “La Sapienza”, Rome, Italy

Alessandro D. Santin, Department of Obstetrics & Gynecology, UAMS Medical Center, AR, USA

Luigi G. Spagnoli, Alliance Against Cancer, Roma, Italy

Karen Strandgaard, European Federation of Pharmaceutical Industries and Associations (EFPIA) Brussels, Belgium

Bhagirath Singh, CIHR Institute of Infection and Immunity, University of Western Ontario, London, Ontario, Canada

Domenica Taruscio, National Center of Rare Diseases, Istituto Superiore di Sanità, Rome, Italy

Glaucio Tocchini-Valentini, Institute of Cellular Biology, National Research Council, Monterotondo, Roma, Italy

Stefano Vella, Department of Therapeutic Research, Istituto Superiore di Sanità, Rome, Italy

Laurent Villard, Institut National de la Santé et de la Recherche Médicale (INSERM), Faculté de Médecine de la Timone, Marseille, France

Robert G. Will, National Creutzfeldt-Jakob Disease Surveillance Unit, University of Edinburgh, Edinburgh, United Kingdom

Magdi H. Yacoub, National Heart and Lung Institute, Imperial College London, South Kensington Campus, London, United Kingdom

Kurt Zatloukal, Institute of Pathology, Medical University of Graz, Graz, Austria

Andreas M. Zeiher, Medical Clinic, Department of Cardiology, University of Freiburg, Germany

Giovanni Zotta, Director, Department of Innovation, Italian Ministry of Labour and Social Welfare